Inflammatory autoimmune disorders such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are life-threatening disorders that affect millions of people worldwide. These conditions have long been associated with an increased risk of cardiovascular diseases (CVD), such as myocardial infarction and ischemic stroke, and the premature cardiovascular mortality drives substantially shortened life expectancy in the patients. While traditional risk factors associated with atherosclerosis including smoking, dyslipidemia, diabetes mellitus (DM), hypertension and increased body mass index (BMI) are present in RA and SLE patients, standard Framingham scores do not fully explain the high rates of CVD events. Thus, autoimmune diseases are regarded as an independent risk factor for the development of cardiovascular comorbidity. Although a key contribution of inflammation to atherogenesis has been implicated, the underlying pathophysiology for CVD in the inflammatory autoimmune diseases remains poorly understood.
Dyslipidemia is a major risk factor for CVD in general population, and statin therapies targeting to lower LDL-cholesterol levels is an effective intervention for prevention of CVD. Although abnormal lipid profiles are also observed in RA or SLE patients, it remains unclear whether they serve as a biomarker to predict future CVD events, and whether they play a key causal role in CVD development. This Research Topic aims to advance the understanding of the role of dyslipidemia in pathogenesis of the inflammatory autoimmune disorders, and to provide further discussion that leads to development of novel therapeutic interventions and more effective preventive modalities against CVD in these conditions.
In this Research Topic, we solicit articles that address the questions of how autoimmune conditions results in dyslipidemia and how lipid abnormality impacts pathogenesis of CVD in autoimmune disorder.
Suggested topics include:
1) Changes in LDL characteristics, such as oxidative state and size, that are associated with or causal to thrombosis and atherosclerosis, underlying conditions to CVD.
2) Abnormal or inflammatory HDL. Ability to exert reverse cholesterol transport, anti-inflammatory, anti-atherogenic cargo molecules such as miRNAs.
3) Contribution of lipoprotein receptors, scavenger receptors on vascular cells (endothelial cells, smooth muscle cells, immune cells such as macrophages, T cells and B cells).
We welcome Original Research articles, Reviews, Brief Research Reports, and Mini Reviews in humans, animal models or in vitro systems
Inflammatory autoimmune disorders such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are life-threatening disorders that affect millions of people worldwide. These conditions have long been associated with an increased risk of cardiovascular diseases (CVD), such as myocardial infarction and ischemic stroke, and the premature cardiovascular mortality drives substantially shortened life expectancy in the patients. While traditional risk factors associated with atherosclerosis including smoking, dyslipidemia, diabetes mellitus (DM), hypertension and increased body mass index (BMI) are present in RA and SLE patients, standard Framingham scores do not fully explain the high rates of CVD events. Thus, autoimmune diseases are regarded as an independent risk factor for the development of cardiovascular comorbidity. Although a key contribution of inflammation to atherogenesis has been implicated, the underlying pathophysiology for CVD in the inflammatory autoimmune diseases remains poorly understood.
Dyslipidemia is a major risk factor for CVD in general population, and statin therapies targeting to lower LDL-cholesterol levels is an effective intervention for prevention of CVD. Although abnormal lipid profiles are also observed in RA or SLE patients, it remains unclear whether they serve as a biomarker to predict future CVD events, and whether they play a key causal role in CVD development. This Research Topic aims to advance the understanding of the role of dyslipidemia in pathogenesis of the inflammatory autoimmune disorders, and to provide further discussion that leads to development of novel therapeutic interventions and more effective preventive modalities against CVD in these conditions.
In this Research Topic, we solicit articles that address the questions of how autoimmune conditions results in dyslipidemia and how lipid abnormality impacts pathogenesis of CVD in autoimmune disorder.
Suggested topics include:
1) Changes in LDL characteristics, such as oxidative state and size, that are associated with or causal to thrombosis and atherosclerosis, underlying conditions to CVD.
2) Abnormal or inflammatory HDL. Ability to exert reverse cholesterol transport, anti-inflammatory, anti-atherogenic cargo molecules such as miRNAs.
3) Contribution of lipoprotein receptors, scavenger receptors on vascular cells (endothelial cells, smooth muscle cells, immune cells such as macrophages, T cells and B cells).
We welcome Original Research articles, Reviews, Brief Research Reports, and Mini Reviews in humans, animal models or in vitro systems
